학술논문

Expert Discussion: ASCO 2021.
Document Type
Interview
Source
Breast Care; 2021, Vol. 16 Issue 4, p429-432, 4p
Subject
THERAPEUTICS
DRUG efficacy
SURVIVAL
GENETIC mutation
HORMONES
IMMUNE checkpoint inhibitors
BRCA genes
CANCER chemotherapy
GENETIC testing
TREATMENT effectiveness
COMBINED modality therapy
BREAST tumors
ENZYME inhibitors
IMMUNOTHERAPY
DRUG toxicity
HORMONE receptor positive breast cancer
Language
ISSN
16613791
Abstract
The article presents an interview with Karen A. Gelmon about breast care. Topics include PARP Inhibitors Ready for Primetime in EBC (Early Breast Cancer) for women with a Germline BRCA Mutation; factors guiding the decision on extended adjuvant hormonal therapy in EBC; and taking-Home Messages from the results of the WGS ADAPT studies for escalating and de-Escalating treatment.